Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Empresas ao redor do mundo buscam proteção com tarifas de Trump
A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...
Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Trump’s $1.4 Trillion Tariff Threat Spurs Companies to Seek Cover
Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
BP plans to sell half its solar arm as the oil giant attempts to win over activist investor Elliott
Pressure is building on BP chief exec Murray Auchincloss (pictured) following reports that Elliott was disappointed with his ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...